Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects
| Autor: | M R, Panara, G, Renda, M G, Sciulli, G, Santini, M, Di Giamberardino, M T, Rotondo, S, Tacconelli, F, Seta, C, Patrono, P, Patrignani |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Adult
Blood Platelets Male Cross-Over Studies Cyclooxygenase 2 Inhibitors Dose-Response Relationship Drug Thiazines Membrane Proteins In Vitro Techniques Meloxicam Dinoprostone Monocytes Isoenzymes Thromboxane B2 Thiazoles Double-Blind Method Cyclooxygenase 2 Prostaglandin-Endoperoxide Synthases Cyclooxygenase 1 Humans Cyclooxygenase Inhibitors Female |
| Zdroj: | The Journal of pharmacology and experimental therapeutics. 290(1) |
| ISSN: | 0022-3565 |
| Popis: | We evaluated whether therapeutic blood levels of meloxicam are associated with selective inhibition of monocyte cyclooxygenase (COX)-2 in vitro and ex vivo. Concentration-response curves for the inhibition of monocyte COX-2 and platelet COX-1 were obtained in vitro after the incubation of meloxicam with whole blood samples. Moreover, 11 healthy volunteers received placebo or 7.5 or 15 mg/day meloxicam, each treatment for 7 consecutive days, according to a randomized, double-blind, crossover design. Before dosing and 24 h after the seventh dose of each regimen, heparinized whole blood samples were incubated with lipopolysaccharide (10 microgram/ml) for 24 h at 37 degrees C, and prostaglandin E2 was measured in plasma as an index of monocyte COX-2 activity. The production of thromboxane B2 in whole blood allowed to clot at 37 degrees C for 60 min was assessed as an index of platelet COX-1 activity. The administration of placebo did not significantly affect plasma prostaglandin E2 (21. 3 +/- 7.5 versus 19.1 +/- 4 ng/ml, mean +/- S.D., n = 11) or serum thromboxane B2 (426 +/- 167 versus 425 +/- 150 ng/ml) levels. In contrast, the administration of 7.5 and 15 mg of meloxicam caused dose-dependent reductions in monocyte COX-2 activity by 51% and 70%, respectively, and in platelet COX-1 activity by 25% and 35%, respectively. Although the IC50 value of meloxicam for inhibition of COX-1 was 10-fold higher than the IC50 value of COX-2 in vitro, this biochemical selectivity was inadequate to clearly separate the effects of meloxicam on the two isozymes after oral dosing as a function of the daily dose and interindividual variation in steady-state plasma levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|